Ofatumumab
Reading tools
Approved by the FDA on 17 April 2014, Arzerra is used with chlorambucil in Chronic Lymphocytic Leukemia patients unresponsive to previous fludarabine-based treatment.
Ofatumumab acts on CD20 on B cells, causing their breakdown. Its most common side effects are low white blood cell counts (neutropenia), headache, susceptibility to herpesvirus, lower respiratory infections, joint pain and abdominal pain.
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.